KLRK1 and plasma cell myeloma: In murine models, NKG2D-CAR T cells demonstrated efficacy in eradicating established multiple myeloma (MM), lymphoma and ovarian cancers and inducing autologous immunity protective against tumor re-challenge after NKG2D-CAR T cells were no longer detectable (23–29).